- Home
- SBFM vs SONN Comparison
SBFM vs SONN Comparison
Compare SBFM & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- SONN
- Stock Information
- Founded
- SBFM 2006
- SONN N/A
- Country
- SBFM United States
- SONN United States
- Employees
- SBFM N/A
- SONN N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- SONN Health Care
- Exchange
- SBFM Nasdaq
- SONN Nasdaq
- Market Cap
- SBFM 6.5M
- SONN 3.8M
- IPO Year
- SBFM N/A
- SONN N/A
- Fundamental
- Price
- SBFM $1.40
- SONN $3.47
- Analyst Decision
- SBFM Strong Buy
- SONN Strong Buy
- Analyst Count
- SBFM 1
- SONN 1
- Target Price
- SBFM $15.00
- SONN $20.00
- AVG Volume (30 Days)
- SBFM 41.6K
- SONN 726.3K
- Earning Date
- SBFM 08-12-2025
- SONN 08-13-2025
- Dividend Yield
- SBFM N/A
- SONN N/A
- EPS Growth
- SBFM N/A
- SONN N/A
- EPS
- SBFM N/A
- SONN N/A
- Revenue
- SBFM $36,341,741.00
- SONN $1,000,000.00
- Revenue This Year
- SBFM $32.20
- SONN $5,376.22
- Revenue Next Year
- SBFM $32.74
- SONN N/A
- P/E Ratio
- SBFM N/A
- SONN N/A
- Revenue Growth
- SBFM 19.22
- SONN 1689.52
- 52 Week Low
- SBFM $1.17
- SONN $1.08
- 52 Week High
- SBFM $3.90
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- SBFM 41.45
- SONN 49.02
- Support Level
- SBFM $1.36
- SONN $2.99
- Resistance Level
- SBFM $1.52
- SONN $3.61
- Average True Range (ATR)
- SBFM 0.07
- SONN 0.48
- MACD
- SBFM -0.00
- SONN 0.01
- Stochastic Oscillator
- SBFM 25.00
- SONN 54.70
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.